Search

Your search keyword '"Tamar Uziel"' showing total 90 results

Search Constraints

Start Over You searched for: Author "Tamar Uziel" Remove constraint Author: "Tamar Uziel"
90 results on '"Tamar Uziel"'

Search Results

51. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

52. The Volume of Three-Dimensional Cultures of Cancer Cells InVitro Influences Transcriptional Profile Differences and Similarities with Monolayer Cultures and Xenografted Tumors

53. Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies

54. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075

55. Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP

56. LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates

57. Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

58. Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

59. Abstract 3831: Selective targeting BET family BDII bromodomain with ABBV-744 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models

60. HEXIM1 as a Robust Pharmacodynamic Marker for Monitoring Target Engagement of BET Family Bromodomain Inhibitors in Tumors and Surrogate Tissues

61. Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors

62. Abstract SY10-03: Cell of origin in pediatric medulloblastomas

63. A Mouse Model of the Most Aggressive Subgroup of Human Medulloblastoma

64. Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

65. Abstract 4960: First-in-class, highly BDII-selective BET family inhibitor ABBV-744 displays potent anti-tumor activity in androgen receptor positive prostate cancer models and an improved tolerability profile

66. Abstract 800: ABBV-744, a first-in-class and highly selective inhibitor of the second bromodomain of BET family proteins, displays robust activities in preclinical models of acute myelogenous leukemia

67. Abstract LB-261: Targeting BET Family Bromodomain with ABBV-075 and BCL-2 with venetoclax (ABT-199) is synergistic in primary acute myeloid leukemia models

68. Author Correction: Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

69. The miR-17 ∼ 92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma

70. Genetic Alterations in Mouse Medulloblastomas and Generation of TumorsDe novofrom Primary Cerebellar Granule Neuron Precursors

71. Requirement of the MRN complex for ATM activation by DNA damage

72. Abstract LB-A23: Discovery of a potent catalytic p300/CBP inhibitor that targets lineage-specific tumors

73. Abstract 3812: JAK2 and PTPN11 mutations as potential biomarkers for BCL-xL inhibition as monotherapy and in combination therapy for acute myeloid leukemia

74. Ataxia-telangiectasia: chronic activation of damage-responsive functions is reduced by α-lipoic acid

75. Ataxia-Telangiectasia Locus: Sequence Analysis of 184 kb of Human Genomic DNA Containing the Entire ATM Gene

76. Ataxia-telangiectasia: structural diversity of untranslated sequences suggests complex post-transcriptional regulation of ATM gene expression

77. Predominance of null mutations in ataxia-telangiectasia

78. Abstract 4738: The BET family bromodomain inhibitor ABBV-075 is a promising therapeutic agent for acute myeloid leukemia and myelodysplastic syndrome

79. Abstract 4706: ABBV-075 exhibits robust in vitro and in vivo activities against the ABC and GCB subtypes of DLBCL

80. Abstract 3770: HEXIM1 as a pharmacodynamic marker for monitoring target engagement of ABBV-075

81. Abstract 420: Translational strategy for targeting MCL1 amplified tumors with CDK9 inhibitor

82. Abstract 4694: ABBV-075, a novel BET family inhibitor, disrupts critical transcription programs that drive prostate cancer growth to induce potent anti-tumor activity in vitro and in vivo

83. Abstract 3085: The BET family bromodomain inhibitor ABBV-075 targets multiple pathogenesis factors in multiple myeloma and exhibits robust in vivo efficacies as a single agent and in combination with bortezomib

84. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines

85. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation

86. A human gene (DDX10) encoding a putative DEAD-box RNA helicase at 11q22-q23

87. Genomic Organization of the ATM gene

88. A single ataxia telangiectasia gene with a product similar to PI-3 kinase

89. Abstract 1434: A mouse model of the most aggressive subgroup of human medulloblastoma

90. Abstract 3444: Enforced expression of MycN and C-Myc induces different medulloblastoma subtypes

Catalog

Books, media, physical & digital resources